Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2017-10-11 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-10-11 English
FORM 3 SUBMISSION
Director's Dealing
2017-10-11 English
FORM 4 SUBMISSION
Director's Dealing
2017-10-11 English
Regulatory Filings 2017
Regulatory Filings
2017-08-24 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to regulatory filing procedures and does not contain financial data, report content, or detailed disclosures. The document is short (2716 characters) and serves as a formal request rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-08-21 English
Regulatory Filings 2017
Regulatory Filings Classification · 70% confidence The provided document text appears to be an encoded or binary file content (e.g., base64 or uuencoded data) rather than readable text. There are no discernible keywords, regulatory headers, fiscal period dates, or document titles that indicate the nature of the filing. The document length is 15,000 characters, which is substantial, but without readable content or metadata indicating the type of report, it is impossible to classify it as a specific financial or regulatory filing. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2017-08-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.